Inovio Pharmaceuticals (NASDAQ: INO) is one of 198 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Inovio Pharmaceuticals to related companies based on the strength of its analyst recommendations, earnings, risk, institutional ownership, profitability, dividends and valuation.


This table compares Inovio Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Inovio Pharmaceuticals -153.46% -63.67% -46.77%
Inovio Pharmaceuticals Competitors -3,945.41% -117.30% -43.55%

Earnings & Valuation

This table compares Inovio Pharmaceuticals and its rivals gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Inovio Pharmaceuticals $51.84 million -$70.60 million -5.48
Inovio Pharmaceuticals Competitors $207.79 million -$2.30 million 0.67

Inovio Pharmaceuticals’ rivals have higher revenue and earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Inovio Pharmaceuticals and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inovio Pharmaceuticals 0 2 8 0 2.80
Inovio Pharmaceuticals Competitors 477 2261 6178 119 2.66

Inovio Pharmaceuticals currently has a consensus target price of $20.20, suggesting a potential upside of 241.22%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.97%. Given Inovio Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Inovio Pharmaceuticals is more favorable than its rivals.

Risk and Volatility

Inovio Pharmaceuticals has a beta of 2.76, meaning that its share price is 176% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals’ rivals have a beta of 1.63, meaning that their average share price is 63% more volatile than the S&P 500.

Insider and Institutional Ownership

25.1% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 48.7% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 10.6% of Inovio Pharmaceuticals shares are held by company insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.